Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
03 04 2021
Historique:
received: 16 07 2020
revised: 21 12 2020
accepted: 03 02 2021
entrez: 4 4 2021
pubmed: 5 4 2021
medline: 18 5 2021
Statut: ppublish

Résumé

Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined as Kidney Disease: Improving Global Outcomes stage 3) until they had oliguria for more than 72 h or a blood urea nitrogen concentration higher than 112 mg/dL. Patients were then randomly assigned (1:1) to either a strategy (delayed strategy) in which RRT was started just after randomisation or to a more-delayed strategy. With the more-delayed strategy, RRT initiation was postponed until mandatory indication (noticeable hyperkalaemia or metabolic acidosis or pulmonary oedema) or until blood urea nitrogen concentration reached 140 mg/dL. The primary outcome was the number of days alive and free of RRT between randomisation and day 28 and was done in the intention-to-treat population. The study is registered with ClinicalTrial.gov, NCT03396757 and is completed. Between May 7, 2018, and Oct 11, 2019, of 5336 patients assessed, 278 patients underwent randomisation; 137 were assigned to the delayed strategy and 141 to the more-delayed strategy. The number of complications potentially related to acute kidney injury or to RRT were similar between groups. The median number of RRT-free days was 12 days (IQR 0-25) in the delayed strategy and 10 days (IQR 0-24) in the more-delayed strategy (p=0·93). In a multivariable analysis, the hazard ratio for death at 60 days was 1·65 (95% CI 1·09-2·50, p=0·018) with the more-delayed versus the delayed strategy. The number of complications potentially related to acute kidney injury or renal replacement therapy did not differ between groups. In severe acute kidney injury patients with oliguria for more than 72 h or blood urea nitrogen concentration higher than 112 mg/dL and no severe complication that would mandate immediate RRT, longer postponing of RRT initiation did not confer additional benefit and was associated with potential harm. Programme Hospitalier de Recherche Clinique.

Sections du résumé

BACKGROUND
Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy.
METHODS
This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined as Kidney Disease: Improving Global Outcomes stage 3) until they had oliguria for more than 72 h or a blood urea nitrogen concentration higher than 112 mg/dL. Patients were then randomly assigned (1:1) to either a strategy (delayed strategy) in which RRT was started just after randomisation or to a more-delayed strategy. With the more-delayed strategy, RRT initiation was postponed until mandatory indication (noticeable hyperkalaemia or metabolic acidosis or pulmonary oedema) or until blood urea nitrogen concentration reached 140 mg/dL. The primary outcome was the number of days alive and free of RRT between randomisation and day 28 and was done in the intention-to-treat population. The study is registered with ClinicalTrial.gov, NCT03396757 and is completed.
FINDINGS
Between May 7, 2018, and Oct 11, 2019, of 5336 patients assessed, 278 patients underwent randomisation; 137 were assigned to the delayed strategy and 141 to the more-delayed strategy. The number of complications potentially related to acute kidney injury or to RRT were similar between groups. The median number of RRT-free days was 12 days (IQR 0-25) in the delayed strategy and 10 days (IQR 0-24) in the more-delayed strategy (p=0·93). In a multivariable analysis, the hazard ratio for death at 60 days was 1·65 (95% CI 1·09-2·50, p=0·018) with the more-delayed versus the delayed strategy. The number of complications potentially related to acute kidney injury or renal replacement therapy did not differ between groups.
INTERPRETATION
In severe acute kidney injury patients with oliguria for more than 72 h or blood urea nitrogen concentration higher than 112 mg/dL and no severe complication that would mandate immediate RRT, longer postponing of RRT initiation did not confer additional benefit and was associated with potential harm.
FUNDING
Programme Hospitalier de Recherche Clinique.

Identifiants

pubmed: 33812488
pii: S0140-6736(21)00350-0
doi: 10.1016/S0140-6736(21)00350-0
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03396757']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1293-1300

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests. The AKIKI 2 trial was promoted by the Assistance Publique—Hôpitaux de Paris and funded by a grant of the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2016; AOM16278).

Auteurs

Stéphane Gaudry (S)

Département de réanimation médico-chirurgicale, APHP Hôpital Avicenne, Bobigny, France; Health Care Simulation Center, UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France; Common and Rare Kidney Diseases, Sorbonne Université, INSERM, UMR-S 1155, Paris, France; Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Bobigny, France.

David Hajage (D)

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France.

Laurent Martin-Lefevre (L)

Réanimation polyvalente, CHR départementale La Roche Sur Yon, La Roche Sur Yon, France.

Saïd Lebbah (S)

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France.

Guillaume Louis (G)

Réanimation polyvalente, CHR Metz-Thionville Hôpital de Mercy, Metz, France.

Sébastien Moschietto (S)

Réanimation polyvalente, CHG d'Avignon Henri Duffaut, Avignon, France.

Dimitri Titeca-Beauport (D)

Réanimation médicale, CHU d'Amiens Picardie, Amiens, France.

Béatrice La Combe (B)

Réanimation, CH de Bretagne Sud, Lorient, France.

Bertrand Pons (B)

Réanimation, CHU Pointe-à-Pitre-Abymes, Pointe-a-Pitre, France.

Nicolas de Prost (N)

Réanimation médicale, Hôpital Henri Mondor, Créteil, France.

Sébastien Besset (S)

Université de Paris, APHP, Hôpital Louis Mourier, DMU ESPRIT, Médecine Intensive-Réanimation, Colombes, France.

Alain Combes (A)

Service de Réanimation Médicale, Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France.

Adrien Robine (A)

Réanimation Soins continus, CH de Bourg-en-Bresse-Fleyriat, 01012 Bourg-en-Bresse, France.

Marion Beuzelin (M)

Réanimation polyvalente, CH de Dieppe, Dieppe, France.

Julio Badie (J)

Réanimation polyvalente, Hôpital Nord Franche-Comte CH Belfort, Belfort, France.

Guillaume Chevrel (G)

Réanimation polyvalente, CH Sud Francilien, Corbeil Essones, France.

Julien Bohé (J)

Anesthésie réanimation médicale et chirurgicale, CH Lyon Sud, Pierre Benite.

Elisabeth Coupez (E)

Réanimation polyvalente, Hôpital G. Montpied, Clermont Ferrand, France.

Nicolas Chudeau (N)

Réanimation médico-chirurgicale, CH du Mans, Le Mans, France.

Saber Barbar (S)

Réanimation, Hôpital Caremeau, Nimes, France.

Christophe Vinsonneau (C)

Réanimation et USC, CH Bethune Beuvry-Bermont et Gauthier, Bethune, France.

Jean-Marie Forel (JM)

Réanimation médicale, Hôpital Nord, Marseille, France.

Didier Thevenin (D)

Réanimation et USC, CH Dr Schaffner, Lens, France.

Eric Boulet (E)

Réanimation et USC, GH Carnelle Portes de l'Oise, Beaumont sur Oise, France.

Karim Lakhal (K)

Réanimation chirurgicale polyvalente, Hôpital Nord laennec, Nantes, France.

Nadia Aissaoui (N)

Réanimation médicale, Hôpital Georges Pompidou, Paris, France.

Steven Grange (S)

Réanimation médicale, CHU Rouen, Rouen, France.

Marc Leone (M)

Anesthésie Réanimation, Hôpital Nord, Marseille, France.

Guillaume Lacave (G)

Réanimation médico-chirurgicale, Hôpital André Mignot, Versailles, France.

Saad Nseir (S)

Réanimation médicale, CHRU de Lille, Hôpital Roger Salengro, Lille, France.

Florent Poirson (F)

Département de réanimation médico-chirurgicale, APHP Hôpital Avicenne, Bobigny, France.

Julien Mayaux (J)

Pneumologie et Réanimation médicale, Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France.

Karim Asehnoune (K)

Anesthésie-réanimation, Hôtel Dieu, Nantes, France.

Guillaume Geri (G)

Réanimation médico-chirurgicale, Hôpital Ambroise Paré, Boulogne-Billancourt, France.

Kada Klouche (K)

Médecine Intensive Réanimation, Hôpital Lapeyronnie, Montpellier, France.

Guillaume Thiery (G)

Réanimation médicale, CHU Saint Etienne, Saint Priest en Jarez, France.

Laurent Argaud (L)

Réanimation médicale, Hôpital Edouard Herriot, Lyon, France.

Bertrand Rozec (B)

Réanimation CTCV, Hôpital Nord laennec, Nantes, France.

Cyril Cadoz (C)

Réanimation polyvalente, CHR Metz-Thionville Hôpital de Mercy, Metz, France.

Pascal Andreu (P)

Médecine intensive réanimation, Hôtel Dieu, Nantes, France.

Jean Reignier (J)

Médecine intensive réanimation, Hôtel Dieu, Nantes, France.

Jean-Damien Ricard (JD)

Université de Paris, APHP, Hôpital Louis Mourier, DMU ESPRIT, Médecine Intensive-Réanimation, Colombes, France; INSERM, IAME, U1137, Paris, France.

Jean-Pierre Quenot (JP)

Department of Intensive Care, François Mitterrand University Hospital, Dijon, France; Lipness Team, INSERM Research Center LNC-UMR1231 and LabExLipSTIC, University of Burgundy, Dijon, France; INSERM CIC 1432, Clinical Epidemiology, University of Burgundy, Dijon, France.

Didier Dreyfuss (D)

Common and Rare Kidney Diseases, Sorbonne Université, INSERM, UMR-S 1155, Paris, France; Université de Paris, APHP, Hôpital Louis Mourier, DMU ESPRIT, Médecine Intensive-Réanimation, Colombes, France. Electronic address: didier.dreyfuss@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH